-+ 0.00%
-+ 0.00%
-+ 0.00%
eXoZymes posts Q3 net loss of $2.24 million; Q3 operating expenses rise 21% to $3.05 million
Share
Listen to the news
eXoZymes posts Q3 net loss of $2.24 million; Q3 operating expenses rise 21% to $3.05 million
  • eXoZymes reported a third-quarter 2026 net loss of $2.24 million.
  • Operating expenses rose 21% year over year to $3.05 million.
  • Quarter-end cash and cash equivalents totaled $3.26 million, expected to support operations through the beginning of 2027.
  • Technology transfer to Curia began in the fourth quarter of 2026, targeting larger-scale NCT manufacturing in 2027.
  • Two additional supplement candidates completed proof of concept; Product SAPPHIRE began scale-up activities.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exozymes Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611191625ACCESSWRNAPR_____1254417) on November 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending